Article: article from journal or magazin.
Outcome parameters for trials in atrial fibrillation: executive summary.
European Heart Journal
Publication types: Consensus Development Conference ; Journal Article ; Research Support. - Old month value: Sep 25
Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.
Anti-Arrhythmia Agents/therapeutic use, Anticoagulants/therapeutic use, Atrial Fibrillation/economics, Atrial Fibrillation/mortality, Catheter Ablation/methods, Costs and Cost Analysis, Electric Countershock/methods, Electrocardiography, Heart Failure/etiology, Hospitalization, Humans, Quality of Life, Randomized Controlled Trials as Topic, Stroke/etiology, Treatment Outcome, Ventricular Dysfunction, Left/etiology
Web of science
Last modification date